NEW USE OF BCG IMMUNOGENIC FORMULATION EXPRESSING A RESPIRATORY SYNCITIAL VIRUS PROTEIN AGAINST hMPV
AssigneePontificia Universidad Catolica De Chile
InventorsAlexis KALERGIS, Susan BUENO, Pablo GONZÁLEZ
Life of this patent
Estimating the term…
Abstract
The invention relates to the novel use of an immunogenic formulation containing the bacillus Calmette-Guérin (BCG) strain at a concentration between 104-109 bacteria, expressing at least one protein or immunogenic fragment of respiratory syncytial virus (RSV, Human orthopneumovirus), in a pharmaceutically acceptable saline buffer solution because it serves to prepare a vaccine useful to prevent, treat, or attenuate human metapneumovirus (hMPV) infections.
Claims11
1-11. (canceled)
Use of an immunogenic formulation containing the Bacillus strain of Calmette and Guerin (BCG), at a concentration between 104-109 bacteria, expressing at least one protein or immunogenic fragment of respiratory syncytial virus (RSV), in a pharmaceutically acceptable saline buffer solution wherein the RSV immunogenic protein or fragment corresponds to the RSV nucleocapsid protein (N protein) and serves to prepare a vaccine useful for preventing, treating, or attenuating human metapneumovirus infections.
Dependencies are inferred from the claim text.